Patricia Inácio, PhD, science writer —

Inhaled nitric oxide (iNO) therapy reduces the risk of death in preterm infants with severe hypoxemic respiratory failure (HRF) — low oxygen in the blood — and suspected or confirmed pulmonary hypertension (PH), a study shows. “The findings provide evidence supporting the prognostic value of oxygenation response and support…

Liquidia is seeking to extend the tentative approval of Yutrepia, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH), to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD occurs when blood pressure in the lungs is high due to a disease that causes lung…

Keros Therapeutics has announced that it will launch a Phase 2 trial to assess the effectiveness of KER-012 as an add-on treatment for patients with pulmonary arterial hypertension (PAH). This follows the recent clearance by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND)…

Pregnant women with mild pulmonary hypertension (PH) show a significantly lower risk of maternal and fetal complications than those with moderate-to-severe PH, according to a study from China. “For patients with mild pulmonary hypertension and good cardiac function, continued pregnancy or even delivery should be considered under multidisciplinary monitoring,”…

Long COVID syndrome can be common among people with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), affecting more than 60% of patients infected with the SARS-CoV-2 virus in a study from Poland. Despite the persistence of COVID-19 symptoms, no change was evident in the patients’ risk of…

People with pulmonary arterial hypertension (PAH) and their caregivers place different value on the parameters used to evaluate clinical worsening in trials, according to the findings of a survey in Canada. Patients attributed significant importance to lacking clinical improvement, needing long-term oxygen therapy, and any decrease in health-related quality…

Using a noninvasive test in conjunction with other assessments may reduce the need to undergo right heart catheterization — a reliable but invasive procedure known as RHC — for diagnosing pulmonary hypertension (PH) in people with interstitial lung disease (ILD), according to a new study. Cardiopulmonary exercise testing (CPET),…

Low blood levels of a protein called brain-derived neurotrophic factor (BDNF) are associated with right heart failure in people with pulmonary arterial hypertension (PAH), a study reports. Experiments in mouse models of PH, however, suggest that the low BDNF levels are a consequence, and not the cause, of right heart failure. The…

Four genes associated with the metabolism of copper in the body have been identified as potential diagnostic biomarkers of pulmonary arterial hypertension (PAH), a new study reports. Researchers used computer software tools to look for specific genes tied to copper metabolism that may serve as less-invasive markers for diagnosing…

The accumulation of aggrecan, a protein found abundantly in cartilage, may be an early response to injury in the lungs of people with idiopathic pulmonary arterial hypertension, a study suggests. Aggrecan accumulated preferentially in blood vessel lesions marked by high blood pressure in the lungs of idiopathic PAH (IPAH)…

People with pulmonary hypertension (PH) who took dipyrone to help manage pain were at a significantly lower risk of assisted ventilation and hospitalization then patients not using this prescription painkiller, according to a large, real-world study. Animal work suggests that dipyrone lowers blood pressure in the pulmonary arteries, and a…

Treatment with C75, an inhibitor of an enzyme called fatty acid synthase (FAS), partially reversed disease processes in a mouse model of pulmonary arterial hypertension (PAH), a study reports. C75 benefits may be linked to changes in pathways involved in cell proliferation and inflammation, among other processes, “thus inhibition…